Optimal management of lipids in diabetes and metabolic syndrome

Journal of Clinical Lipidology

Volumn 2, Issue 5, 2008, Pages 335-342

  Brown, W Virgil ^a   Clark, Luther ^b   Falko, James M ^c   Guyton, John R ^d   Rees, Tomas J ^e   Schonfeld, Gustav ^f   Lopes Virella, Maria F ^g  

^a EMORY UNIVERSITY   (United States)

^b MERCK RESEARCH LABORATORIES   (United States)

^c UNIVERSITY OF COLORADO   (United States)

^d DUKE UNIVERSITY MEDICAL CENTER   (United States)

^e PAREXEL INTERNATIONAL   (United States)

^f WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

Cholesterol; Diabetes; Dyslipidemia; Fibrates; High density lipoprotein; Metabolic syndrome; Niacin; Statins

Indexed keywords

ANTILIPEMIC AGENT; APOLIPOPROTEIN B; ATORVASTATIN; EZETIMIBE; EZETIMIBE PLUS SIMVASTATIN; FENOFIBRATE; FIBRIC ACID DERIVATIVE; GEMFIBROZIL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LAROPIPRANT PLUS NICOTINIC ACID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NICOTINIC ACID; NICOTINIC ACID PLUS SIMVASTATIN; PLACEBO; SIMVASTATIN; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ADJUVANT THERAPY; ARTERY INTIMA PROLIFERATION; CARDIOVASCULAR RISK; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CORONARY ARTERY ATHEROSCLEROSIS; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; DYSLIPIDEMIA; FAMILIAL HYPERCHOLESTEROLEMIA; FLUSHING; GLYCEMIC CONTROL; HIGH RISK PATIENT; HUMAN; INSULIN RESISTANCE; LIFESTYLE MODIFICATION; METABOLIC SYNDROME X; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PATIENT COMPLIANCE; PRIORITY JOURNAL; REVIEW; RHABDOMYOLYSIS; RISK REDUCTION; SIDE EFFECT;

EID: 53449093270     PISSN: 19332874     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jacl.2008.08.444     Document Type: Review

References (47)

1. Wild S., Roglic G., Green A., Sicree R., and King H. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 27 (2004) 1047-1053
2. American Diabetes Association. Economic costs of diabetes in the US in 2007. Diabetes Care 31 (2008) 1-20
3. Huxley R., Barzi F., and Woodward M. Excess risk of fatal coronary heart disease associated with diabetes in men and women: meta-analysis of 37 prospective cohort studies. BMJ 332 (2006) 73-78
4. Yan S.F., Ramasamy R., Naka Y., and Schmidt A.M. Glycation, inflammation, and RAGE: a scaffold for the macrovascular complications of diabetes and beyond. Circ Res 93 (2003) 1159-1169
5. Downs J.R., Clearfield M., Weis S., et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA 279 (1998) 1615-1622
6. Colhoun H.M., Betteridge D.J., Durrington P.N., et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 364 9435 (2004) 685-696
7. Knopp R.H., d'Emden M., Smilde J.G., and Pocock S.J. Efficacy and safety of atorvastatin in the prevention of cardiovascular end points in subjects with type 2 diabetes: the Atorvastatin Study for Prevention of Coronary Heart Disease Endpoints in non-insulin-dependent diabetes mellitus (ASPEN). Diabetes Care 29 (2006) 1478-1485
8. Chapman M. Metabolic syndrome and type 2 diabetes: lipid and physiological consequences. Diabetes Vasc Dis Res 4 suppl 3 (2007) S5-S8
9. Brunzell J.D., Davidson M., Furberg C.D., et al. Lipoprotein management in patients with cardiometabolic risk: consensus statement from the American Diabetes Association and the American College of Cardiology Foundation. Diabetes Care 31 (2008) 811-822
10. Singh I.M., Shishehbor M.H., and Ansell B.J. High-density lipoprotein as a therapeutic target: a systematic review. JAMA 298 (2007) 786-798
11. Schaefer E.J., McNamara J.R., Shah P.K., et al. Elevated remnant-like particle cholesterol and triglyceride levels in diabetic men and women in the Framingham Offspring Study. Diabetes Care 25 (2002) 989-994
12. Kathiresan S., Otvos J.D., Sullivan L.M., et al. Increased small low-density lipoprotein particle number: a prominent feature of the metabolic syndrome in the Framingham Heart Study. Circulation 113 (2006) 20-29
13. St-Pierre A.C., Cantin B., Dagenais G.R., et al. Low-density lipoprotein subfractions and the long-term risk of ischemic heart disease in men: 13-year follow-up data from the Quebec Cardiovascular Study. Arterioscler Thromb Vasc Biol 25 (2005) 553-559
14. Prospective Studies Collaboration, Lewington S., Whitlock G., et al. Blood cholesterol and vascular mortality by age, sex, and blood pressure: a meta-analysis of individual data from 61 prospective studies with 55,000 vascular deaths. Lancet 370 (2007) 1829-1839
15. Drexel H., Aczel S., Marte T., et al. Is atherosclerosis in diabetes and impaired fasting glucose driven by elevated LDL cholesterol or by decreased HDL cholesterol?. Diabetes Care 28 (2005) 101-107
16. Brown B.G., Stukovsky K.H., and Zhao X.Q. Simultaneous low-density lipoprotein-C lowering and high-density lipoprotein-C elevation for optimum cardiovascular disease prevention with various drug classes, and their combinations: a meta-analysis of 23 randomized lipid trials. Curr Opin Lipidol 17 (2006) 631-636
17. Sarwar N., Danesh J., Eiriksdottir G., et al. Triglycerides and the risk of coronary heart disease: 10,158 incident cases among 262,525 participants in 29 Western prospective studies. Circulation 115 (2007) 450-458
18. Bansal S., Buring J.E., Rifai N., Mora S., Sacks F.M., and Ridker P.M. Fasting compared with nonfasting triglycerides and risk of cardiovascular events in women. JAMA 298 (2007) 309-316
19. National Cholesterol Education Program. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) Final Report. Circulation 106 (2002) 3143-3421
20. American Diabetes Association. Standards of Medical Care in Diabetes-2008. Diabetes Care 31 suppl 1 (2008) S12-S54
21. IDF Clinical Guidelines Task Force. Global guideline for type 2 diabetes. http://www.idf.org/ Accessed July 3, 2008
22. McPherson R., Frohlich J., Fodor G., Genest J., and Canadian Cardiovascular Society. Canadian Cardiovascular Society position statement-recommendations for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease. Can J Cardiol 22 (2006) 913-927
23. Grundy S.M., Cleeman J.I., Merz C.N., et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. J Am Coll Cardiol 44 (2004) 720-732
24. Fletcher B., Berra K., Ades P., et al. Managing abnormal blood lipids: a collaborative approach. Circulation 112 (2005) 3184-3209
25. Ahmed S., Cannon C.P., Murphy S.A., and Braunwald E. Acute coronary syndromes and diabetes: Is intensive lipid lowering beneficial?. Results of the PROVE IT-TIMI 22 trial. Eur Heart J 27 (2006) 2323-2329
26. Rubins H.B., Robins S.J., Collins D., et al. Diabetes, plasma insulin, and cardiovascular disease: subgroup analysis from the Department of Veterans Affairs high-density lipoprotein intervention trial (VA-HIT). Arch Intern Med 162 (2002) 2597-2604
27. Otvos J.D., Collins D., Freedman D.S., et al. Low-density lipoprotein and high-density lipoprotein particle subclasses predict coronary events and are favorably changed by gemfibrozil therapy in the Veterans Affairs High-Density Lipoprotein Intervention Trial. Circulation 113 (2006) 1556-1563
28. Wierzbicki A.S. Fibrates after the FIELD study: some answers, more questions. Diab Vasc Dis Res 3 (2006) 166-171
29. Keech A.C., Mitchell P., Summanen P.A., et al. Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study): a randomised controlled trial. Lancet 370 (2007) 1687-1697
30. Keech A., Simes R.J., Barter P., et al. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet 366 (2005) 1849-1861
31. Keech A. Effects of long-term fenofibrate therapy on cardiovascular events among 9795 people with type 2 diabetes mellitus: the FIELD study, a randomised controlled trial. Atheroscler Suppl 7 (2006) 342
32. Denke M., Pearson T., McBride P., Gazzara R.A., Brady W.E., and Tershakovec A.M. Ezetimibe added to ongoing statin therapy improves LDL-C goal attainment and lipid profile in patients with diabetes or metabolic syndrome. Diab Vasc Dis Res 3 (2006) 93-102
33. Brown B.G. Niaspan in the management of dyslipidemia: the evidence. Eur Heart J 8 suppl F (2006) F60-F67
34. Thoenes M., Oguchi A., Nagamia S., et al. The effects of extended-release niacin on carotid intimal media thickness, endothelial function and inflammatory markers in patients with the metabolic syndrome. Int J Clin Pract 61 (2007) 1942-1948
35. Canner P.L., Furberg C.D., and McGovern M.E. Benefits of niacin in patients with versus without the metabolic syndrome and healed myocardial infarction (from the Coronary Drug Project). Am J Cardiol 97 (2006) 477-479
36. Costa J., Borges M., David C., and Vaz Carneiro A. Efficacy of lipid lowering drug treatment for diabetic and non-diabetic patients: meta-analysis of randomised controlled trials. BMJ 332 (2006) 1115-1124
37. Kearney P.M., Blackwell L., and Cholesterol Treatment Trialists' (CTT) Collaborators. Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis. Lancet 371 (2008) 117-125
38. Law M., and Rudnicka A.R. Statin safety: a systematic review. Am J Cardiol 97 8A (2006) 52C-60C
39. Ballantyne C.M., Davidson M.H., McKenney J., Keller L.H., Bajorunas D.R., and Karas R.H. Comparison of the Safety and Efficacy of a Combination Tablet of Niacin Extended Release and Simvastatin vs Simvastatin Monotherapy in Patients With Increased Non-HDL Cholesterol (from the SEACOAST I Study). Am J Cardiol 101 (2008) 1428-1436
40. Vittone F., Chait A., Morse J.S., Fish B., Brown B.G., and Zhao X.Q. Niacin plus simvastatin reduces coronary stenosis progression among patients with metabolic syndrome despite a modest increase in insulin resistance: a subgroup analysis of the HDL-Atherosclerosis treatment study. J Clin Lipidol 1 (2007) 203-210
41. Saaddine J.B., Cadwell B., Gregg E.W., et al. Improvements in diabetes processes of care and intermediate outcomes: United States, 1988-2002. Ann Intern Med 144 (2006) 465-474
42. Grant R.W., and Meigs J.B. Prevalence and treatment of low HDL cholesterol among primary care patients with type 2 diabetes: an unmet challenge for cardiovascular risk reduction. Diabetes Care 30 (2007) 479-484
43. Falko J.M., Moser R.J., Meis S.B., and Caulin-Glaser T. Cardiovascular disease risk of type 2 diabetes mellitus and metabolic syndrome: focus on aggressive management of dyslipidemia. Curr Diabetes Rev 1 (2005) 127-135
44. Tenenbaum A., Fisman E.Z., Motro M., and Adler Y. Atherogenic dyslipidemia in metabolic syndrome and type 2 diabetes: therapeutic options beyond statins. Cardiovasc Diabetol 5 (2006) 20
45. Lai E., De Lepeleire I., Crumley T.M., et al. Suppression of niacin-induced vasodilation with an antagonist to prostaglandin D2 receptor subtype 1. Clin Pharmacol Ther 81 (2007) 849-857
46. Canner P.L., Furberg C.D., Terrin M.L., and McGovern M.E. Benefits of niacin by glycemic status in patients with healed myocardial infarction (from the Coronary Drug Project). Am J Cardiol 95 (2005) 254-257
47. Kung H.C., Hoyert D.L., Xu J., and Murphy S.L. Deaths: final data for 2005. Natl Vital Stat Rep 56 (2008) 10